Edition:
India

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

5.84EUR
22 Aug 2019
Change (% chg)

-- (--)
Prev Close
€5.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
138,362
52-wk High
€9.44
52-wk Low
€4.51

Summary

Name Age Since Current Position

Herve Brailly

57 2016 Chairman of the Supervisory Board

Mondher Mahjoubi

60 2016 Chairman of the Executive Board, Chief Executive Officer

Irina Staatz-Granzer

58 2009 Independent Vice Chairman of the Supervisory Board

Laure-Helene Mercier

40 2016 Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Jerome Tiollier

59 2014 Executive Vice President in charge of Operations, Member of the Executive Committee, Chief Development Officer

Yannis Morel

45 2017 Executive Vice President Products Portfolio Strategy & Business Development, Member of the Executive Board

Jennifer Butler

2019 Executive Vice President, General Manager, US

Pierre Dodion

62 2014 Executive Vice President, Chief Medical Officer, Member of the Executive Committee

Eric Vivier

2018 Senior Vice President, Chief Scientific Officer, Guest Member of the Executive Committee

Gilles Brisson

66 2016 Independent Member of the Supervisory Board

Veronique Chabernaud

57 2015 Independent Member of the Supervisory Board

Patrick Langlois

71 2010 Independent Member of the Supervisory Board

Jean-Yves Blay

56 2017 Member of the Supervisory Board

Mailys Ferrere

56 2017 Member of the Supervisory Board, Representative of Bpifrance Participations

Marcus Schindler

52 2018 Member of the Supervisory Board, Representative of Novo Nordisk

Biographies

Name Description

Herve Brailly

Mr. Herve Brailly has been Chairman of the Supervisory Board of Innate Pharma S.A. since December 30, 2016. He is also Member of the Audit Committee and the Compensation and Nominations Committee at the Company. He co-founded Innate Pharma in 1999 and was Chairman of the Executive Board and Chief Executive Officer until December 30, 2016. He was previously a researcher at Immunotech SA, a biotechnology start up acquired in 1995 by Beckman-Coulter (1986-1994), where he later became responsible for marketing, business development and R&D, as well as the business activities in China (1994-1998). From 1998, Mr. Brailly was the director of a business unit of the company. He is a graduate of the Ecole des Mines de Paris (1983) and a Doctor of Immunology, with a specialization in immuno-pharmacology.

Mondher Mahjoubi

Dr. Mondher Mahjoubi, M.D., has been Chairman of the Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016. He is responsible for general management, general corporate policy and Human resources at the Company. Prior to joining Innate Pharma, Dr. Mahjoubi led the Oncology Therapy area at AstraZeneca beginning in November 2013 and was Oncology Global Manager from August 2016. In that role, he had direct responsibility for oncology global medical affairs and United States medical affairs. Prior to AstraZeneca, he was the Senior Vice President of global product strategy in oncology at Genentech from 2010 to 2013 and he previously held positions in marketing and medical affairs for Roche, Mayne Pharma, Sanofi-Aventis and Rhone Poulenc Rorer. Dr. Mahjoubi holds a M.D. from the University of Tunis and certifications in Medical Oncology from the University of Tunis and University of Paris Sud and in Clinical Research and Methodology from the University of Lariboisiere-Saint Louis. He is trained as a medical oncologist and is a member of the American Society of Clinical Oncology and European Society of Medical Oncology.

Irina Staatz-Granzer

Ms. Irina Staatz-Granzer has been Independent Vice Chairman of the Supervisory Board of Innate Pharma S.A. since June 23, 2009. She is Member of the Audit Committee and Chairwoman of the Transaction Committee at the Company. Ms. Staatz-Granzer held several business development positions, mostly at Hermal, Boots Healthcare International, Knoll and Scil Biomedicals. Ms. Staatz-Granzer also serves as Chairman of Blink Biomedicals and Talix Therapeutics NV. She founded and is currently President of Staatz Business Development & Strategy. Ms. Staaz-Granzer received a degree in pharmacy from Philipps-Universitaet Marburg and a Ph.D. from the University of Tuebingen.

Laure-Helene Mercier

Ms. Laure-Helene Mercier has been Chief Financial Officer, Executive Vice President and Member of the Executive Committee of Innate Pharma S.A. since December 30, 2016. She joined Innate Pharma in 2007. Prior to her current position, Ms. Mercier served as Executive Vice President, Finance beginning in October 2016 and was previously the Company's Director of Investor Relations. Prior to joining, Ms. Mercier held positions as an equity analyst at Oddo Securities and Natexis Bleichroeder. She has a Master of Science in Neurosciences from Universite Aix-Marseille and a MBA from ESSEC Business School.

Jerome Tiollier

Dr. Jerome Tiollier, Ph.D., has been Executive Vice President in charge of Operations, Member of the Executive Committee, Chief Development Officer at Innate Pharma S.A. since 2014. Prior to that, he was Member of the Executive Board, Executive Vice President - Development. He joined Innate in September 2001. Dr. Tiollier is a graduate of the University of Lyon and holds a doctorate in cellular biology and immunology. He previously worked at IMEDEX SA, a division of the Institut Merieux (1986-1997), before joining the business unit IMTIX Transplant of Pasteur Merieux (acquired by SANGSTAT in 1998) as Director of preclinical development (1997-1999) and Director of Research and Development Europe (1999-2001). In this latter position, he managed pharmaceutical projects (including Thymoglobulin and Antilfa) and was involved in the Group's medication research activities.

Yannis Morel

Mr. Yannis Morel, Ph.D., has been Executive Vice President Products Portfolio Strategy & Business Development and Member of the Executive Board of Innate Pharma S.A. since June 23, 2017. He was Executive Vice President - Business Development and Member of the Executive Board at the Company from December 12, 2015. Prior to that, he served as Executive Vice President and Chief Business Officer and Member of the Executive Committee of the Company from 2011. He joined the Company in December 2001. From 2001 to 2007, he held a number of positions in Research and Development at the Company, from Immunology Researcher to Team Leader and then Head of Research and Development Programs. He has been in charge of business development at the Company since 2007. Mr. Morel holds a Doctorate in oncology from Universite Aix-Marseille and is also a graduate of Ecole Normale Superieure de Cachan with a BS in physical and molecular chemistry.

Jennifer Butler

Ms. Jennifer Butler has been appointed Executive Vice President, General Manager, US of the company as of March 11, 2019. Ms. Butler leads Innate Pharma's US corporate activities focusing on the establishment of the Company's US operations to fully support the commercialization of Lumoxiti ® . She collaborates with Innate's global commercial team to support Lumoxiti's future potential launches in Europe and life cycle management. Ms. Butler will be part of the Executive Committee of Innate Pharma and report directly into Mondher Mahjoubi, Chief Executive Officer.

Pierre Dodion

Dr. Pierre F. Dodion, M.D., has been Executive Vice President, Chief Medical Officer and Member of the Executive Committee of Innate Pharma S.A. since September 2014. He has 25 years of experience in Medical affairs in the pharmaceutical industry having worked at Pfizer (2006-2008), Novartis (2002-2006) and Aventis (1996-2002). He contributed to the development, approval and launch of several drugs. In 2007, Dr. Dodion joined ARIAD Pharmaceuticals, first as SVP and Chief Medical Officer, then as SVP Corporate Development and Operations. He played a role in the expansion of ARIAD, notably in Europe. He is a medical doctor, with a specialization degree in Oncology from the Free University of Brussels, Belgium and an MBA degree from the Saint Joseph University of Philadelphia, PA.

Eric Vivier

Prof. Eric Vivier has been Senior Vice President, Chief Scientific Officer, Guest Member of the Executive Committee at Innate Pharma as of January 8, 2018. He is a Doctor of Veterinary Medicine (DVM) from the Ecole Nationale Veterinaire de Maisons-Alfort and holds a PhD in Immunology from the Paris University (Paris XI). After completing his post-doctoral fellowship at Harvard Medical School (Dana Faber Cancer Institute), Pr. Vivier joined the Center of Immunology at Marseille-Luminy (CIML) in 1993, becoming its director in 2008 until 2017. He has twice been laureate of the prestigious European Research Council (ERC) advanced grants. During his career, Pr. Vivier has been a visiting professor at The Scripps Research Institute, The Rockefeller University, and The Walter and Elisa Hall Institute. He is a member of the French National Academy of Medicine and of the Institut Universitaire de France. He is on the board of numerous committees and has been awarded several prices and honors, including the European Federation of Immunological Society award and the Grand Prix Charles Oberling in Oncology. He is also Chevalier de la Legion d’Honneur.

Gilles Brisson

Mr. Gilles Brisson has been Independent Member of the Supervisory Board of Innate Pharma S.A. since December 30, 2016. Prior to that, he was Independent Chairman of the Supervisory Board at the Company. He joined the Company's Supervisory Board on June 26, 2007. He is Member of the Audit Committee and Chairman of the Compensation and Nominations Committee at the Company. Mr. Brisson has worked in management positions at Rhone-Poulenc and then at Aventis Pharma, where he served as Chairman of the Executive Board, Chairman of the Supervisory Board and Europe Manager. Mr. Brisson also serves as Chairman of the Supervisory Board of Ethypharm and Member of the Supervisory Board of the Group Carso. He received a degree from Hautes Etudes Commerciales de Paris.

Veronique Chabernaud

Ms. Veronique Chabernaud has been Independent Member of the Supervisory Board of Innate Pharma S.A. since April 27, 2015. She is Member of the Compensation and Nominating Committee at the Company. Ms. Chabernaud is an oncologist and has worked for 20 years in the pharmaceutical industry. In particular, she was the Director of the French Oncological Operational Unit at Sanofi Aventis, a Vice President of Marketing and Sales at Aventis Intercontinental and Europe, and Director of Oncology Global Medical Affairs at Rhone Poulenc Rorer. She has also consulted with companies in France and abroad. Such companies include Genomic Health, BioSystems International, MaunaKea Technologies and Ariana Pharma. In 2007, Ms. Chabernaud founded Creer la Vitalite, which helps companies and organizations in the development of a global health approach. Ms. Chabernaud also founded the association “Enfance et Vitalite” which offers health workshops to children. She is a graduate of ESSEC Business School and has a M.D. in Medicine, Oncology and Cancer Biology from Faculte Xavier Bichat in Paris.

Patrick Langlois

Mr. Patrick Langlois has been Independent Member of the Supervisory Board of Innate Pharma S.A. since May 25, 2010. He is Chairman of the Audit Committee and Member of the Compensation and Nominations Committee at the Company. Mr. Langlois has been Associate Managing Director of PJL Conseils since 2005. He worked for the Rhone-Poulenc group starting in 1975 and was appointed the Financial Director in 1997, where he served until 1999. From 2000 through 2004, he worked at Aventis. Mr. Langlois also serves as the Chairman of the Board of Directors of French company Sensorion SA and a Director of Newron (Italy). He received a Ph.D. in Economics from the University of Rennes.

Jean-Yves Blay

Prof. Jean-Yves Blay has been Member of the Supervisory Board of Innate Pharma SA since December 13, 2017. He has held the post of General Director of the Centre Leon Berard in Lyon, France, since 2014 and in 2016 became Secretary of the Oncology Commission of the French Academy of Medicine. Between 2009 and 2012 he held the position of President of the European Organization for Research and Treatment of Cancer (EORTC). Prof. Blay currently holds various other university and hospital positions. He is a member of the European Union Committee of Experts of Rare Disease; the European Commission’s Scientific Panel for Health (SPH) and served as a Faculty Coordinator for Sarcoma for the European Society of Medical Oncology (ESMO) between 2012 and 2016. Trained as a medical oncologist with a PhD from the University Claude Bernard in Lyon, his research activities have been focused on the role of immune effector cells and cytokines in cancer. Prof. Blay is a member of various scientific societies and academic expert groups, has been awarded several honors and is the author of more than 200 publications over the last three years.

Mailys Ferrere

Ms. Mailys Ferrere has been Member of the Supervisory Board and Representative of Bpifrance Participations at Innate Pharma S.A. since June 23, 2017. She is Member of the Audit Committee. She is Director of the Large Venture Investment team within the Innovation Division of Bpifrance. Prior to this position, she was an Investment Director at the Strategic Investment Fund between 2009 and 2012. She previously had a career in banking, focusing on equity capital markets in various financial institutions. She is Member of the Boards of Directors or Supervisory boards of the following companies: DBV, Valneva SE and Euronext Paris. She graduated from Societe Francaise des Analystes Financiers, and received a degree in Law from Institut d'Etudes Politiques de Paris.

Marcus Schindler

Mr. Marcus Schindler has been Member of the Supervisory Board representing Novo Nordisk at Innate Pharma as of March 7, 2018. He is Senior Vice President of External Innovation & Strategy at Novo Nordisk A/S. This area is responsible for identifying, establishing and maintaining all external deals and collaborations up to and including Clinical Proof of Concept within all therapy areas. Prior to this occupation, Mr. Schindler was VP, Head of the Cardiovascular & Metabolic Diseases and Head of Research at Novo Nordisk A/S. Previously he was member of Executive Management Committee, (OSI) Prosidion, based in Oxford, UK, held senior positions at Boehringer Ingelheim and at Glaxo Wellcome’s blue skies research institute, “Glaxo Institute of Applied Pharmacology”, Cambridge, UK. Mr. Schindler received his PhD in Pharmacology from the University of Cambridge and holds a position as adjunct Professor of Pharmacology at the University of Gothenburg. He as co-/authored 50+ peer-reviewed research papers and is an inventor of 25 international patent applications.